Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

The influence of steroid metabolism on CYP17A1 inhibitor activity

Nature Reviews Urology volume 14, pages 590–592 (2017)Cite this article

Subjects

Galeterone is a steroid 17-α-hydroxylase/17,20 lyase and androgen receptor antagonist intended for patients with prostate cancer. Similar to abiraterone, galeterone has a steroid scaffold structure and mimics natural ligands; thus, these agents are metabolized by the same enzymes that synthesize or degrade naturally occurring steroids, which can result in attenuated efficacy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: CYP17A1 inhibitor metabolites and their properties.

References

  1. Alyamani, M. et al. Steroidogenic metabolism of galeterone reveals a diversity of biochemical activities. Cell Chem. Biol. 24, 825–832.e6 (2017).

    Article  CAS  Google Scholar 

  2. Li, Z. et al. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature 533, 547–551 (2016).

    Article  CAS  Google Scholar 

  3. Attard, G., Belldegrun, A. S. & de Bono, J. S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 96, 1241–1246 (2005).

    Article  Google Scholar 

  4. Yin, L. & Hu, Q. CYP17 inhibitors — abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat. Rev. Urol. 11, 32–42 (2014).

    Article  CAS  Google Scholar 

  5. James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1702900 (2017).

  6. Handratta, V. D. et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 48, 2972–2984 (2005).

    Article  CAS  Google Scholar 

  7. Yu, Z. et al. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin. Cancer Res. 20, 4075–4085 (2014).

    Article  CAS  Google Scholar 

  8. Nilsson, M. E. et al. Measurement of a comprehensive sex steroid profile in rodent serum by high-sensitive gas chromatography-tandem mass spectrometry. Endocrinology 156, 2492–2502 (2015).

    Article  CAS  Google Scholar 

  9. Laurent, M. R. et al. Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis. Sci. Rep. 6, 35539 (2016).

    Article  CAS  Google Scholar 

  10. Li, Z. et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 523, 347–351 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cellular and Molecular Medicine, Frank Claessens is at the Molecular Endocrinology Laboratory, Campus Gasthuisberg, Herestraat 49, PO Box 901, 3000 Leuven, Belgium.,

    Frank Claessens

  2. Department of Cellular and Molecular Medicine, Belgium; and at the Department of Urology, Lisa Moris is at the Molecular Endocrinology Laboratory, Campus Gasthuisberg, Herestraat 49, PO Box 901, 3000 Leuven, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.,

    Lisa Moris

  3. and at the Department of Urology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.,

    Lisa Moris

Authors
  1. Frank Claessens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Moris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank Claessens.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Claessens, F., Moris, L. The influence of steroid metabolism on CYP17A1 inhibitor activity. Nat Rev Urol 14, 590–592 (2017). https://doi.org/10.1038/nrurol.2017.132

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2017.132

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research